CO5700705A2 - Composiciones y metodos para la administracion mejorada por via mucosa de peptidos fijadores al receptor de y2 y metodos para tratar y prevenir la obesidad - Google Patents

Composiciones y metodos para la administracion mejorada por via mucosa de peptidos fijadores al receptor de y2 y metodos para tratar y prevenir la obesidad

Info

Publication number
CO5700705A2
CO5700705A2 CO05058645A CO05058645A CO5700705A2 CO 5700705 A2 CO5700705 A2 CO 5700705A2 CO 05058645 A CO05058645 A CO 05058645A CO 05058645 A CO05058645 A CO 05058645A CO 5700705 A2 CO5700705 A2 CO 5700705A2
Authority
CO
Colombia
Prior art keywords
methods
peptides
treat
receiver
compositions
Prior art date
Application number
CO05058645A
Other languages
English (en)
Inventor
Steven Quay
Original Assignee
Nastech Pharm Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/322,266 external-priority patent/US7166575B2/en
Application filed by Nastech Pharm Co Inc filed Critical Nastech Pharm Co Inc
Publication of CO5700705A2 publication Critical patent/CO5700705A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

1.- Una formulación del péptido fijador al receptor de Y2 para la administración transmucosa capaz de aumentar la concentración del péptido fijador al receptor de Y2 en el plasma de un mamífero en al menos 5 pmol o más por litro cuando se administra una dosis que contiene 50 µg del agonista del péptido fijador al receptor de Y2 por vía transmucosa al mamífero.
CO05058645A 2002-12-17 2005-06-16 Composiciones y metodos para la administracion mejorada por via mucosa de peptidos fijadores al receptor de y2 y metodos para tratar y prevenir la obesidad CO5700705A2 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/322,266 US7166575B2 (en) 2002-12-17 2002-12-17 Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US49322603P 2003-08-07 2003-08-07
US50117003P 2003-09-08 2003-09-08
US51078503P 2003-10-10 2003-10-10
US51729003P 2003-11-04 2003-11-04
US51881203P 2003-11-10 2003-11-10

Publications (1)

Publication Number Publication Date
CO5700705A2 true CO5700705A2 (es) 2006-11-30

Family

ID=32686401

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05058645A CO5700705A2 (es) 2002-12-17 2005-06-16 Composiciones y metodos para la administracion mejorada por via mucosa de peptidos fijadores al receptor de y2 y metodos para tratar y prevenir la obesidad

Country Status (13)

Country Link
US (4) US7186691B2 (es)
EP (1) EP1581245A2 (es)
JP (1) JP2006516262A (es)
AU (1) AU2003299722A1 (es)
BR (1) BR0316685A (es)
CA (1) CA2510199A1 (es)
CO (1) CO5700705A2 (es)
EA (1) EA008829B1 (es)
EC (1) ECSP055839A (es)
MA (1) MA27535A1 (es)
MX (1) MXPA05006572A (es)
NO (1) NO20053430L (es)
WO (1) WO2004056314A2 (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU779986B2 (en) 1999-06-29 2005-02-24 Mannkind Corporation Purification and stabilization of peptide and protein pharmaceutical agents
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2300568T3 (es) 2002-03-20 2008-06-16 Mannkind Corporation Aparato de inhalacion.
EP1583549A4 (en) * 2003-01-17 2006-10-04 Sod Conseils Rech Applic YY PEPTIDE ANALOGS
WO2005072710A2 (en) * 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
US20050181456A1 (en) * 2004-02-09 2005-08-18 Nastech Pharmaceutical Company Inc. Methods for determining the amount of peptide YY in blood
US7279457B2 (en) 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
EP2057996A3 (en) * 2004-03-17 2009-11-04 7TM Pharma A/S Y4 selective receptor agonists for therapeutic intervention
US20070213270A1 (en) * 2004-06-16 2007-09-13 Costantino Henry R Peptide yy formulations having increased stability and resistance to microbial agents
NZ552558A (en) * 2004-07-12 2009-11-27 Emisphere Tech Inc Compositions for delivering peptide YY and PYY agonists
MX2007000728A (es) * 2004-07-21 2007-03-15 Ambrx Inc Polipeptidos biosinteticos que utilizan amino acidos no naturalmente codificados.
MX2007001903A (es) 2004-08-20 2007-08-02 Mannkind Corp Catalisis de sintesis de dicetopiperazina.
KR101306384B1 (ko) 2004-08-23 2013-09-09 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는디케토디옥산염
PA8660701A1 (es) * 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
KR100953469B1 (ko) * 2005-02-08 2010-04-16 우드포드 어소시에이츠 리미티드 1h216o가 강화된 알콜 함유 음료
BRPI0520021A2 (pt) * 2005-02-08 2009-04-14 Woodford Associates Ltd bebidas não alcoólicas enriquecidas com 1h2 16o
CN101137416A (zh) * 2005-03-05 2008-03-05 谢尔盖帕夫洛维奇·索洛维约夫 富含1h216o的化妆品组合物
EA012187B1 (ru) * 2005-03-11 2009-08-28 Вада Консалтинг Лимитед Способы для интрадермальной, трансдермальной или трансмукозальной доставки биологически активных веществ
US20080160100A1 (en) * 2005-03-11 2008-07-03 Igor Anatolievich Pomytkin Method For Stimulating Hair Growth And Regeneration
EA012822B1 (ru) * 2005-03-11 2009-12-30 Вада Консалтинг Лимитед Композиции для дезинфекции поверхностей неодушевленных предметов
CN101146543A (zh) * 2005-03-11 2008-03-19 维达咨询有限公司 轻制药用水和治疗组合物及其制备方法
RU2275920C1 (ru) * 2005-04-01 2006-05-10 Игорь Анатольевич Помыткин Способ лечения новообразований
CA2614619A1 (en) * 2005-07-11 2007-01-18 Nastech Pharmaceutical Company Inc. Formulations for enhanced mucosal delivery of pyy
JP5465878B2 (ja) 2005-09-14 2014-04-09 マンカインド コーポレイション 活性薬剤に対する結晶性微粒子表面の親和性を増大させることに基づく薬物処方の方法
EP1971350A1 (en) * 2005-12-12 2008-09-24 VADA Consulting Limited Method of treating metabolic syndrome
US20080292718A1 (en) * 2005-12-12 2008-11-27 Igor Anatolievich Pomytkin Method for Suppression Appetite and Food Intake
WO2007070563A2 (en) * 2005-12-13 2007-06-21 Harkness Pharmaceuticals, Inc. Stable solid forms of enterostatin
AU2006326502A1 (en) * 2005-12-13 2007-06-21 Harkness Pharmaceuticals, Inc. Methods of treating obesity using enterostatin
US20070149442A1 (en) * 2005-12-13 2007-06-28 Byron Rubin Non-hygroscopic compositions of enterostatin
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
EP2029157A4 (en) 2006-05-19 2009-11-18 Georgia Tech Res Inst LIGAND OF CARRIERS ABC
RU2301067C1 (ru) * 2006-06-19 2007-06-20 Сергей Павлович Соловьев Средство и способ для повышения половой активности человека
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
JP2009542813A (ja) * 2006-07-11 2009-12-03 ハルクネスス プハルマセウティカルス，インコーポレイテッド 飽食因子を使用して肥満を治療する方法
EP2049138A4 (en) 2006-07-14 2011-11-09 Georgia Tech Res Inst CLC KANALLIGAND
CN101511868B (zh) 2006-07-24 2013-03-06 比奥雷克西斯制药公司 毒蜥外泌肽融合蛋白
WO2008030557A2 (en) * 2006-09-08 2008-03-13 Johns Hopkins University Compositions and methods for enhancing transport through mucus
GB0708226D0 (en) * 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US8889622B2 (en) * 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
US20100210559A1 (en) * 2007-09-11 2010-08-19 Mondobiotech Laboratories Ag Trap-14 as a therapeutic agent
SG188143A1 (en) * 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
EP2265630B1 (en) 2008-04-14 2014-10-29 The General Hospital Corporation Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN104689432B (zh) 2008-06-13 2018-07-06 曼金德公司 干粉吸入器和用于药物输送的系统
JP5479465B2 (ja) 2008-06-20 2014-04-23 マンカインド コーポレイション 吸入努力をリアルタイムにプロファイルする対話式機器および方法
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US20110230399A1 (en) * 2008-11-25 2011-09-22 Bowen Richard L Methods for Treating Obesity Related Disease
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
PL2405963T3 (pl) 2009-03-11 2014-04-30 Mannkind Corp Urządzenie, układ i sposób pomiaru oporu inhalatora
EP2440184B1 (en) 2009-06-12 2023-04-05 MannKind Corporation Diketopiperazine microparticles with defined specific surface areas
JP5767582B2 (ja) 2009-07-02 2015-08-19 武田薬品工業株式会社 ペプチド及びその用途
EP2464365A2 (en) * 2009-08-14 2012-06-20 Allergan, Inc. Methods of treating cancer using tachykinin retargeted endopeptidases
US8207651B2 (en) 2009-09-16 2012-06-26 Tyco Healthcare Group Lp Low energy or minimum disturbance method for measuring frequency response functions of ultrasonic surgical devices in determining optimum operating point
KR101026864B1 (ko) 2009-10-08 2011-04-12 (주)송호바이오메드 고 수용성 ２―하이드록시프로필―베타사이클로덱스트린을 유효성분으로 함유하는 비만 질환 예방 및 치료용 조성물
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US8974826B2 (en) 2010-06-10 2015-03-10 Monosol Rx, Llc Nanoparticle film delivery systems
RU2571331C1 (ru) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
DK2694402T3 (en) 2011-04-01 2017-07-03 Mannkind Corp BLISTER PACKAGE FOR PHARMACEUTICAL CYLINDER AMPULS
RU2476227C2 (ru) * 2011-04-14 2013-02-27 Ольга Георгиевна Мельникова Способ снижения избыточного веса
DE102011103347B4 (de) * 2011-05-27 2014-10-30 Meda Pharma Gmbh & Co. Kg Nasale pharmazeutische Formulierung
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
EP3406247A1 (en) 2011-12-11 2018-11-28 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
EA030318B1 (ru) 2012-03-16 2018-07-31 Дзе Джонс Хопкинс Юниверсити Конъюгаты нелинейного мультиблочного сополимера с лекарственным средством для доставки активных агентов
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2844227B1 (en) 2012-05-03 2020-11-18 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
MX360107B (es) 2012-11-13 2018-10-23 Adocia Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido.
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
ES2729970T3 (es) * 2013-04-10 2019-11-07 Univ Copenhagen Péptidos derivados de neuropéptidos y
BR112016000937A8 (pt) 2013-07-18 2021-06-22 Mannkind Corp formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
US20170081366A1 (en) * 2015-09-22 2017-03-23 Kyungpook National University Industry - Academic Cooperation Foundation Novel Peptides for Preventing or Treating Bone Diseases and Use Thereof
EA038755B1 (ru) 2015-11-12 2021-10-14 Грейбаг Вижн, Инк. Агрегирующие микрочастицы для обеспечения замедленного высвобождения терапевтического агента для внутриглазной доставки
CN111201040A (zh) 2017-05-10 2020-05-26 灰色视觉公司 用于医学疗法的缓释微粒及其悬浮液
US20200062823A1 (en) * 2017-05-16 2020-02-27 The University Of Chicago Compositions and methods for treating and/or preventing pathogenic fungal infection and for maintenance of microbiome commensalism
WO2019147650A1 (en) * 2018-01-23 2019-08-01 Gila Therapeutics, Inc. Peptide yy pharmaceutical formulations, compositions, and methods
WO2023046336A1 (en) * 2021-09-22 2023-03-30 Ferring B.V. Adrenocorticotropic hormone peptide compositions and methods of use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH657779A5 (de) 1982-10-05 1986-09-30 Sandoz Ag Galenische zusammensetzungen enthaltend calcitonin.
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5725804A (en) 1991-01-15 1998-03-10 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
ATE147976T1 (de) 1991-01-15 1997-02-15 Hemosphere Inc Protein nanomatrizen und verfahren zur herstellung
US6391343B1 (en) 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
US5616311A (en) 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
HU213531B (en) 1992-07-07 1997-07-28 Continental Pet Technologies Method of forming multilayer product, especially container, bottle, and multilayer container, bottle, made from multilayer material and preform forming the container, the bottle
PL174772B1 (pl) 1993-01-06 1998-09-30 Kinerton Ltd Kompozycja farmaceutyczna zawierająca jonowy konjugat cząsteczkowy
KR960701653A (ko) 1993-03-29 1996-03-28 발라수브라마니암 엠비카이파칸 펩타이드 yy의 유사체 및 그의 용도
CN1055700C (zh) 1993-08-09 2000-08-23 生物测量公司 治疗用肽衍生物
US5696093A (en) 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5912227A (en) 1995-01-27 1999-06-15 North Carolina State University Method of enhancing nutrient uptake
CA2220451A1 (en) 1995-05-17 1996-11-21 Cedars-Sinai Medical Center Methods and compositions for improving digestion and absorption in the small intestine
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US5716643A (en) 1995-06-07 1998-02-10 Hemosphere Inc. Large scale production of medicine coated crosslinked protein microspheres
US6017897A (en) * 1995-06-07 2000-01-25 Pasteur Merieux Connaught Canada Nucleic acid respiratory syncytial virus vaccines
FR2736265B1 (fr) * 1995-07-07 1997-09-26 Forgeot Marcel Nouvelles compositions a base de phosphoglycero ethers et leur utilisation dans le traitement des maladies neuro-degeneratives
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6013633A (en) 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU1159897A (en) 1996-11-13 1998-06-03 University Of Cincinnati, The Analogs of peptide yy and uses thereof
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
WO1998055105A1 (en) 1997-06-05 1998-12-10 Hemosphere, Inc. Fibrinogen-coated microspheres
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
IT1293088B1 (it) 1997-07-10 1999-02-11 Isi Ist Sierovaccinogeno Ital Microparticelle per il rilascio controllato di molecole biologicamente attive e loro uso in terapia, profilassi e diagnostica in vitro e in
US6737408B1 (en) 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
WO1999015516A1 (fr) 1997-09-25 1999-04-01 Banyu Pharmaceutical Co., Ltd. Nouveaux antagonistes des recepteurs de neuropeptides y
JP2002501907A (ja) 1998-01-29 2002-01-22 キナートン・リミテッド 吸収可能なマイクロ粒子の製造法
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
US5968748A (en) 1998-03-26 1999-10-19 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human HER-2 expression
US6017879A (en) 1998-04-03 2000-01-25 B.M.R.A. Corporation B.V. Template associated NPY Y2-receptor agonists
US7745216B2 (en) * 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
JP2003518914A (ja) 1999-02-10 2003-06-17 キュリス インコーポレイテッド グルコース代謝障害を治療する方法および試薬
US6391855B1 (en) * 1999-06-02 2002-05-21 Adherex Technologies, Inc. Compounds and methods for modulating junctional adhesion molecule-mediated functions
BR0116206A (pt) 2000-12-14 2003-12-23 Amylin Pharmaceuticals Inc Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos
EP2050460A1 (en) 2001-09-24 2009-04-22 Imperial Innovations Limited PYY and agonists thereof for modification of feeding behaviour
US20050014681A1 (en) 2001-11-26 2005-01-20 Yoshiharu Minamitake Medicinal compositions for nasal absorption
JP4733922B2 (ja) 2002-01-10 2011-07-27 インペリアル・イノベ−ションズ・リミテッド 摂食行動の修正
ATE494002T1 (de) 2002-06-14 2011-01-15 Amylin Pharmaceuticals Inc Prävention und/oder behandlung von colitis ulcerosa mit pyy oder pyyä3-36ü

Also Published As

Publication number Publication date
EP1581245A2 (en) 2005-10-05
EA008829B1 (ru) 2007-08-31
NO20053430L (no) 2005-09-15
WO2004056314A3 (en) 2005-03-31
BR0316685A (pt) 2005-11-01
ECSP055839A (es) 2006-03-01
US7186691B2 (en) 2007-03-06
MXPA05006572A (es) 2005-12-14
US20070129299A1 (en) 2007-06-07
US20070197437A1 (en) 2007-08-23
US7157426B2 (en) 2007-01-02
WO2004056314A2 (en) 2004-07-08
NO20053430D0 (no) 2005-07-14
MA27535A1 (fr) 2005-09-01
EA200501007A1 (ru) 2006-02-24
US20040209807A1 (en) 2004-10-21
CA2510199A1 (en) 2004-07-08
AU2003299722A1 (en) 2004-07-14
US20040157777A1 (en) 2004-08-12
WO2004056314B1 (en) 2005-09-29
JP2006516262A (ja) 2006-06-29

Similar Documents

Publication Publication Date Title
CO5700705A2 (es) Composiciones y metodos para la administracion mejorada por via mucosa de peptidos fijadores al receptor de y2 y metodos para tratar y prevenir la obesidad
PE20060880A1 (es) Conjugados de polipeptido y un pentasacarido que tienen propiedades farmacocineticas mejoradas
IL160222A0 (en) Opioid agonist formulations with releasable and sequestered antagonist
UY27465A1 (es) Métodos y composiciones para tratar flavivirus y pestivirus con 4' modificaciones nucleosides
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
ZA200606173B (en) Effervescent oral opiate dosage form
CL2012000348A1 (es) Metodo para tratar o reducir la gravedad de la osteoporosis u osteopenia en un paciente que comprende administrarle el compuesto n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida o una sal del mismo; composicion farmaceutica.
SG157415A1 (en) Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
ES2147309T3 (es) Composiciones de ondansetron liofilizadas.
CO5090908A1 (es) Procedimiento para administrar peptidos insulinotropicos
TR201903603T4 (tr) Hareket bozukluklarının tedavisinde kullanım için A2A reseptörü antagonistleri.
AR033444A1 (es) Forma solida de dosificacion util para la administracion oral de un compuesto activo de nicotina, a traves de la mucosa y uso de un compuesto activo de nicotina para prepararla
EA200100284A1 (ru) Агонисты 5ht1 рецепторов и метоклопрамид для лечения мигрени
UY25078A1 (es) Composiciones farmacéuticas que contienen eletriptan hemisulfato estabilizadas con cafeína
NZ593190A (en) Factor viii formulations
EA200801369A1 (ru) Способы трансдермального введения агониста рецептора индолсеротонина и трансдермальные лекарственные формы для применения этого способа
GEP20053568B (en) NMDA Receptor Agonist Pharmaceutical Compositions
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
IL167890A (en) Use of a chorionic gonadotropin in the preparation of a medicament for treating a chronic pelvic pain syndrome
AR072516A1 (es) Metodos, sistemas y dispositivos para la administracion de dioxido de cloro a un tejido
WO2005058252A3 (en) Glp-1 pharmaceutical compositions
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
UY27800A1 (es) Utilizacion de inhibidores de la transduccion de senales inducida por egfr para el tratamiento de la hiperplasia de la prostata benigna (hps) /hipertrofia de la prostata.
NO20080552L (no) GLP-1 farmasoytiske sammensetninger
BR0209155A (pt) Tablete farmacêutico tendo um teor de api elevado

Legal Events

Date Code Title Description
FC Application refused